Biocardia Inc Financials
Biocardia Inc (BCDA) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioCardia is being financed as a development-stage program, with external capital replacing missing commercial revenue while annual cash burn stays near $8M .
From FY2023 through FY2025, net loss and operating cash outflow moved almost in lockstep—in FY2025,-$8.2M versus-$7.4M —while capital spending was only$7K . That combination says the company’s cash need comes mainly from funding R&D and overhead, not from building a heavy asset base, so fresh financing rather than operating scale has been keeping the business going.
In FY2025, financing inflow of
The current ratio recovered from 0.4x in FY2023 to 1.1x in FY2025 and equity turned positive again, so the short-term balance-sheet squeeze eased. But cash of
Financial Health Signals
Biocardia Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Biocardia Inc scores -73.31, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($15.3M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Biocardia Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Biocardia Inc reported a net loss of $8.2M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Biocardia Inc generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Biocardia Inc's EBITDA was -$8.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.0% from the prior year.
Biocardia Inc reported -$8.2M in net income in fiscal year 2025. This represents a decrease of 3.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Biocardia Inc recorded an outflow of $7.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 5.7% from the prior year.
Biocardia Inc held $2.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Biocardia Inc's ROE was -919.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 30.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Biocardia Inc invested $5.0M in research and development in fiscal year 2025. This represents an increase of 13.1% from the prior year.
Biocardia Inc invested $7K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 16.7% from the prior year.
Not reported for fiscal year 2025.
BCDA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0-100.0% | $58K-87.8% | $477K-64.7% | $1.4M+33.2% | $1.0M+600.0% | $145K-79.6% | $710K+13.6% | $625K+30.5% | $479K-16.8% | $576K-36.3% | $904K | N/A | N/A | $62K+416.7% | $12K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $4K-98.9% | $358K-30.8% | $517K-25.1% | $690K-7.5% | $746K-29.7% | $1.1M | N/A | N/A | $0 | $0 |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $1.0M+619.9% | $141K-59.9% | $352K+225.9% | $108K+151.2% | -$211K-24.1% | -$170K-8.3% | -$157K | N/A | N/A | $62K+416.7% | $12K |
| R&D Expenses | N/A | $5.0M+13.1% | $4.4M-43.2% | $7.7M-12.5% | $8.8M+3.2% | $8.6M-12.8% | $9.8M+14.6% | $8.6M+1.3% | $8.5M+45.8% | $5.8M+74.1% | $3.3M+119.4% | $1.5M | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $3.3M-9.7% | $3.7M-16.5% | $4.4M-0.5% | $4.4M-13.1% | $5.1M-13.2% | $5.9M-2.4% | $6.0M+4.3% | $5.8M-10.0% | $6.4M+55.7% | $4.1M+10.0% | $3.7M+1805.1% | $196K-24.3% | $259K-35.4% | $401K-36.3% | $630K |
| Operating Income | N/A | -$8.3M-3.5% | -$8.0M+31.3% | -$11.6M+2.2% | -$11.9M+5.8% | -$12.6M+18.7% | -$15.5M-9.3% | -$14.2M-0.8% | -$14.1M-13.7% | -$12.4M-63.1% | -$7.6M-40.7% | -$5.4M-2441.6% | $231K+2466.7% | $9K+102.7% | -$339K+45.1% | -$618K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $3K-97.3% | $112K | N/A | $0-100.0% | $1.7M+25.3% | $1.4M | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$8.2M-3.5% | -$7.9M+31.3% | -$11.6M+2.8% | -$11.9M+5.7% | -$12.6M+15.9% | -$15.0M-2.0% | -$14.7M-5.2% | -$14.0M-13.6% | -$12.3M-19.4% | -$10.3M-53.9% | -$6.7M-2962.0% | $234K+1131.6% | $19K-93.8% | $305K-96.8% | $9.7M |
Not reported in any period shown, so not listed: EPS (Diluted).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCDA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.4M-8.4% | $3.7M+24.7% | $3.0M-69.5% | $9.8M-37.7% | $15.7M-32.9% | $23.4M+205.1% | $7.7M+19.7% | $6.4M-52.6% | $13.5M-38.7% | $22.1M+354.2% | $4.9M-65.0% | $13.9M+2.4% | $13.5M+1.8% | $13.3M-3.2% | $13.7M |
| Current Assets | $2.7M+4.2% | $2.6M+79.5% | $1.5M-81.4% | $7.9M-41.7% | $13.5M-40.5% | $22.7M+255.3% | $6.4M+2.6% | $6.2M-53.3% | $13.3M-39.2% | $21.9M+369.4% | $4.7M | N/A | N/A | $13.3M-3.2% | $13.7M |
| Cash & Equivalents | $2.5M+5.3% | $2.4M+115.0% | $1.1M-85.0% | $7.4M-42.8% | $12.9M-39.9% | $21.4M+283.3% | $5.6M+4.2% | $5.4M-57.8% | $12.7M-40.6% | $21.4M+500.3% | $3.6M+11.7% | $3.2M-76.1% | $13.3M+0.2% | $13.3M+4.7% | $12.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $4K-97.2% | $141K-26.2% | $191K+41.5% | $135K-82.2% | $759K | N/A | N/A | N/A | N/A |
| Accounts Receivable | $20K | $0-100.0% | $63K-68.7% | $201K+36.7% | $147K-36.6% | $232K+57.8% | $147K-46.4% | $274K+188.4% | $95K+28.4% | $74K-30.8% | $107K | N/A | N/A | $0-100.0% | $67K |
| Total Liabilities | $2.5M-12.8% | $2.9M-37.1% | $4.6M-6.3% | $4.9M-8.3% | $5.3M+25.8% | $4.2M-20.0% | $5.3M+102.2% | $2.6M+8.8% | $2.4M+60.9% | $1.5M-81.9% | $8.3M-85.4% | $57.0M+5699200.0% | $1K-91.7% | $12K-98.4% | $756K |
| Current Liabilities | $2.4M+4.8% | $2.3M-35.7% | $3.6M+0.6% | $3.6M-3.4% | $3.7M-12.6% | $4.2M+6.1% | $4.0M+57.1% | $2.5M+9.3% | $2.3M+61.5% | $1.4M-82.6% | $8.3M | N/A | N/A | N/A | N/A |
| Total Equity | $895K+6.9% | $837K+152.2% | -$1.6M-132.8% | $4.9M-52.8% | $10.4M-45.9% | $19.2M+709.1% | $2.4M-37.5% | $3.8M-65.9% | $11.1M-45.9% | $20.6M+698.0% | -$3.4M+92.0% | -$43.1M-423.9% | $13.3M+0.2% | $13.3M+2.4% | $13.0M |
| Retained Earnings | -$168.3M-5.1% | -$160.1M-5.2% | -$152.2M-8.2% | -$140.6M-9.3% | -$128.7M-10.9% | -$116.1M-14.8% | -$101.1M-17.0% | -$86.4M-19.2% | -$72.5M-20.5% | -$60.1M-20.7% | -$49.8M-310.7% | -$12.1M+2.6% | -$12.5M+2.0% | -$12.7M+2.3% | -$13.0M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BCDA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.6M | -$7.4M+5.7% | -$7.9M+20.9% | -$10.0M+5.6% | -$10.6M-1.9% | -$10.4M+16.1% | -$12.4M-30.8% | -$9.4M+14.7% | -$11.1M-27.7% | -$8.7M-57.0% | -$5.5M+21.4% | -$7.0M-3381.8% | $214K+692.6% | $27K+108.7% | -$310K+90.0% | -$3.1M |
| Capital Expenditures | $9K | $7K+16.7% | $6K-50.0% | $12K-82.9% | $70K-39.7% | $116K+262.5% | $32K-78.1% | $146K+121.2% | $66K-51.5% | $136K | N/A | $125K | N/A | N/A | $0-100.0% | $137K |
| Free Cash Flow | -$7.6M | -$7.4M+5.7% | -$7.9M+21.0% | -$10.0M+6.1% | -$10.6M-1.4% | -$10.5M+15.4% | -$12.4M-29.2% | -$9.6M+13.9% | -$11.1M-26.4% | -$8.8M | N/A | -$7.1M | N/A | N/A | -$310K+90.4% | -$3.2M |
| Investing Cash Flow | -$9K | -$7K-16.7% | -$6K+50.0% | -$12K+82.9% | -$70K+39.7% | -$116K-262.5% | -$32K+78.1% | -$146K-121.2% | -$66K+51.5% | -$136K-100.7% | $18.9M+15236.8% | -$125K | N/A | $0-100.0% | $900K-94.4% | $16.1M |
| Financing Cash Flow | $10.7M | $7.6M-17.4% | $9.2M+145.8% | $3.7M-27.3% | $5.1M+163.1% | $1.9M-93.1% | $28.2M+187.3% | $9.8M+158.1% | $3.8M+2541.7% | $144K-96.7% | $4.4M-41.6% | $7.5M | N/A | N/A | $0+100.0% | -$500K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCDA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | 100.0%+2.8pp | 97.2%+47.7pp | 49.6%+32.3pp | 17.3%+61.3pp | -44.0%-14.5pp | -29.5%-12.1pp | -17.4% | N/A | N/A | 100.0%0.0pp | 100.0% |
| Operating Margin | N/A | -13794.8% | -2441.1% | -880.3% | -1244.3% | -10709.7% | -2001.8% | -2256.3% | -2589.8% | -1320.8% | -598.3% | N/A | N/A | -546.8% | -5150.0% |
| Net Margin | N/A | -13700.0% | -2425.8% | -880.7% | -1243.7% | -10347.6% | -2071.7% | -2237.9% | -2569.5% | -1789.9% | -740.8% | N/A | N/A | 491.9% | 80516.7% |
| Return on Equity | -919.3%+30.0pp | -949.3% | N/A | -243.4%-121.7pp | -121.7%-43.4pp | -78.2%+542.4pp | -620.6%-251.8pp | -368.9%-258.2pp | -110.6%-60.5pp | -50.1% | N/A | N/A | 0.1%-2.2pp | 2.3%-72.2pp | 74.5% |
| Return on Assets | -241.1%-27.7pp | -213.4%+174.0pp | -387.4%-265.8pp | -121.6%-41.3pp | -80.3%-16.3pp | -64.0%+127.5pp | -191.6%+26.4pp | -218.0%-127.1pp | -90.9%-44.2pp | -46.7%+91.0pp | -137.7%-139.4pp | 1.7%+1.5pp | 0.1%-2.2pp | 2.3%-68.1pp | 70.3% |
| Current Ratio | 1.120.0x | 1.13+0.7x | 0.40-1.8x | 2.19-1.4x | 3.63-1.7x | 5.33+3.7x | 1.59-0.8x | 2.44-3.3x | 5.71-9.5x | 15.18+14.6x | 0.56 | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 2.81-0.6x | 3.45 | N/A | 1.00+0.5x | 0.52+0.3x | 0.22-2.0x | 2.24+1.5x | 0.69+0.5x | 0.22+0.1x | 0.07 | N/A | N/A | 0.000.0x | 0.00-0.1x | 0.06 |
| FCF Margin | N/A | -13606.9% | -2093.5% | -786.3% | -1032.7% | -8544.1% | -1350.8% | -1781.6% | -1838.6% | N/A | -790.7% | N/A | N/A | -500.0% | -26866.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Biocardia Inc Ranks
Frequently Asked Questions
What is Biocardia Inc's annual revenue?
Biocardia Inc (BCDA) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biocardia Inc's revenue growing?
Biocardia Inc (BCDA) revenue declined by 100.0% year-over-year, from $58K to $0 in fiscal year 2025.
Is Biocardia Inc profitable?
No, Biocardia Inc (BCDA) reported a net income of -$8.2M in fiscal year 2025.
What is Biocardia Inc's EBITDA?
Biocardia Inc (BCDA) had EBITDA of -$8.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biocardia Inc's return on equity (ROE)?
Biocardia Inc (BCDA) has a return on equity of -919.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biocardia Inc's free cash flow?
Biocardia Inc (BCDA) recorded an outflow of $7.4M in free cash flow during fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biocardia Inc's operating cash flow?
Biocardia Inc (BCDA) recorded an outflow of $7.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biocardia Inc's total assets?
Biocardia Inc (BCDA) had $3.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biocardia Inc's capital expenditures?
Biocardia Inc (BCDA) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biocardia Inc spend on research and development?
Biocardia Inc (BCDA) invested $5.0M in research and development during fiscal year 2025.
What is Biocardia Inc's current ratio?
Biocardia Inc (BCDA) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
What is Biocardia Inc's debt-to-equity ratio?
Biocardia Inc (BCDA) had a debt-to-equity ratio of 2.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biocardia Inc's return on assets (ROA)?
Biocardia Inc (BCDA) had a return on assets of -241.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biocardia Inc's cash runway?
Based on fiscal year 2025 data, Biocardia Inc (BCDA) had $2.5M in cash against an annual operating cash burn of $7.4M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Biocardia Inc's Altman Z-Score?
Biocardia Inc (BCDA) has an Altman Z-Score of -73.31, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Biocardia Inc's Piotroski F-Score?
Biocardia Inc (BCDA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biocardia Inc's earnings high quality?
Biocardia Inc (BCDA) reported a net loss of $8.2M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.